project
commercialisation of CyCol
Advanced Manufacturing process
Pharmaceutical product Application
innovative product
oral product
nanoemulsion-based technology
technology platform
patients
Phase
human studies
Scale
SAMPA
leading EU-based specialist SME technology
Sigmoid Pharma
underlying SmPill
Successful development
Successful completion
Sigmoidâ€™s proprietary SmPill
equipment suppliers
long term high skill jobs
know-how
moderate-severe ulcerative colitis
cyclosporine
probability of overall company success
disease
intellectual property
risk of serious
expensive drugs
powerful drug
batch size
value inherent
number of knowledge providers
effects
NPV
requested budget
colons
Europe
batches
months